SCHEMBL146118

SCHEMBL146118

Cc1c(Br)cccc1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP2A6 P11509 2/20 0.46
TRIM24 O15164 3/20 0.43
TRIM33 Q9UPN9 3/20 0.43
KCNJ1 P48048 1/20 0.43
ERN1 O75460 3/20 0.41
TLR2 O60603 1/20 0.39
TLR1 Q15399 1/20 0.39
TLR6 Q9Y2C9 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
PIM1 P11309 1/20 0.39
PIM3 Q86V86 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29621617 1.00 ALDH1A1 (0.50) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL2451551 0.90 ALDH1A1 (0.59) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL22675489 0.90 ALDH1A1 (0.42) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL6015132 0.81 ALDH1A1 (0.39) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL22675472 0.80 ALDH1A1 (0.37) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL22675473 0.80 ALDH1A1 (0.37) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL22675476 0.80 KCNJ1 (0.37) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL22675468 0.80 KCNJ1 (0.37) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL40633 0.78 LMNA (0.50) ALDH1A1TSHRMEN1LMNATHRB
SCHEMBL29444 0.78 TSHR (0.65) ALDH1A1TSHRMEN1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720038-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2026-04-08 EP disclosed
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 US disclosed
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER SOPONPONG JAKAPUN (TH) 2025-11-27 US disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 US disclosed
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS GENENTECH, INC. (US) 2025-07-17 US disclosed
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2025-07-10 US disclosed
EP-4566675-A2 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2025-06-11 EP disclosed
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2025-05-29 US disclosed
CN-119948027-A SOS1 protein degradation agent and application thereof 领泰生物医药(绍兴)有限公司 2025-05-06 CN disclosed
CN-119613400-A Heterocyclic compounds as immunomodulators 因赛特公司 2025-03-14 CN disclosed
EP-1689712-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS Novartis AG (CH) 2006-08-16 EP disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
CN-1665800-A Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2005-09-07 CN disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
WO-2005051911-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2005-06-09 WO disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed
US-5750631-A CURABLE EPOXIDIZED PHENOLIC RESIN CONTAINING CHLORINE AND/OR BROMINE; FIREPROOFING, BY-PRODUCT INHIBITION SHELL OIL COMPANY (US) 1998-05-12 US disclosed
EP-0054180-A2 Process for the preparation of imidazoquinazoline derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ALDH1A1 3674/4885TSHR 110/4885MEN1 1309/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ALDH1A1 2779/4885TSHR 247/4885MEN1 1088/4885
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, IL5, TSLP ALDH1A1 666/4885TSHR 3037/4885MEN1 1465/4885
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 ALDH1A1 1759/4885TSHR 573/4885MEN1 3586/4885
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS CBLB, CBL, CBLC ALDH1A1 4354/4885TSHR 3923/4885MEN1 2646/4885
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER PDCD1, CD274, PDCD1LG2 ALDH1A1 36/4885TSHR 1650/4885MEN1 2605/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 ALDH1A1 409/4885TSHR 54/4885MEN1 3035/4885
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS ALDH1A1 247/4885TSHR 2281/4885MEN1 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.